Toxic Side Effects of Platinum Analogs

Schurig, John E.; Bradner, William T.; Huftalen, James B.; Doyle, Gary J.; Gylys, J. A.

doi:10.1016/b978-0-12-565050-2.50018-8

Cited by 12 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the doses tested, cis-DDP did not show a very high toxic ity against these tissues. In this sense, it is im portant for the newly designed platinum com plexes not to increase considerably this host tissue toxicity, which is apparently a limiting factor in cancer chemotherapy [1][2][3][4]. The pre sent results show that compound I meets these requirements.…”

Section: Discussionmentioning

confidence: 60%

“…Introduction cis-Diamminedichloroplatinum (II) (cis platin, cis-DDP) was the first metal complex ototoxicity, neurotoxicity and myelosuppression, as well as by its low solubility [1,2], In or der to reduce these toxic effects, second-gen eration cis-DDP analogs have been synthe sized, showing significant differences in their organ and myelotoxicity [3][4][5]. Prominent among them was carboplatin (cis-diamminecyclobutanedicarboxylatoplatinum), an ana log with higher solubility and reduced renal toxicity [5].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of DNA Synthesis in Different Tissues of L1210-Leukemia-Bearing Mice by New Platinum (II) Complexes

Gorneva

Grancharov²,

Spassovska³

1993

Chemotherapy

View full text Add to dashboard Cite

The inhibition of [¹⁴C]thymidine incorporation into DNA of tumor and normal tissues of L1210-leukemia-bearing mice by single doses of cis-diamminedichloroplatinum (II) (cisplatin, cis-DDP) and two newly synthesized platinum (II) complexes containing as ligands dimethyl aminomethylphosphine oxide (complex I) and methyl bis(aminomethyl)phosphine oxide (complex II) was studied and used as an indication of drug toxicity. All three complexes caused selective inhibition of precursor incorporation in L1210 cells as compared to host tissue cells. cis-DDP caused a complete block of incorporated thymidine in tumor cells during more than 48 h, whereas in intestinal mucosa and bone marrow reverse inhibition was observed. In spleen, liver and kidney the inhibition was about 50% and endured up to 96 h without reversal. Complex I treatment of L1210 cells resulted in an earlier recovery of thymidine incorporation into DNA in comparison with cis-DDP. Towards all other normal tissues compound I was less toxic than cis-DDP. Unlike cis-DDP and complex I, complex II was less active against L1210 cells and most toxic against bone marrow and kidney.

show abstract

Section: Discussionmentioning

confidence: 60%

mentioning

confidence: 99%

Inhibition of DNA Synthesis in Different Tissues of L1210-Leukemia-Bearing Mice by New Platinum (II) Complexes

Gorneva

Grancharov²,

Spassovska³

1993

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…The dosages used in the present study were less than the lethal dose for nude mice and about one-third of the LD50 for conventional mice, reported by other investigators (Wilkinson et al, 1978;Bradner et al, 1980;Schurig et al, 1980;Shepherd et al, 1980;Lelieveld et al, 1984). The doses used here are in the right range because they appear equally toxic in terms of mean body weight as a percentage of starting weight.…”

mentioning

confidence: 81%

Antitumour activity of platinum analogues against human yolk sac tumours heterotransplanted in nude mice

Sawada¹,

Matsui²,

Okudaira³

1986

Br J Cancer

View full text Add to dashboard Cite

“…The activity of cis-platin is attributed to bifunctional crosslinking between DNA and proteins, resulting in inhibition of DNA replication and on subsequent RNA transcription [2,3]. However, cis-platin is highly toxic and can cause severe side effects such as thrombocytopenia, gastrointestinal, renal and neurological toxicities [4].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Degradation Properties of Polyglycolide and Its Potential as Delivery Vehicle for Anticancer Agents

Noorsal¹,

Ghani²,

Yunos³

et al. 2010

AIP Conference Proceedings

View full text Add to dashboard Cite

Biodegradable polymers offer a unique combination of properties that can be tailored to suit nearly any controlled drug delivery application. The most common biodegradable polymers used for biomedical applications are semicrystalline polyesters and polyethers which possess good mechanical properties and have been used in many controlled release applications. Drug release from these polymers may be controlled by several mechanisms and these include diffusion of drug through a matrix, dissolution of polymer matrix and degradation of the polymer. This study aims to investigate the degradation and drug release properties of polyglycolide (1.03 dL/g), in which, cis platin, an anticancer agent was used as the model drug. The degradation behaviour of the chosen polymer is thought to largely govern the release of the anticancer agent in vitro.

show abstract

Toxic Side Effects of Platinum Analogs

Cited by 12 publications

References 6 publications

Inhibition of DNA Synthesis in Different Tissues of L1210-Leukemia-Bearing Mice by New Platinum (II) Complexes

Inhibition of DNA Synthesis in Different Tissues of L1210-Leukemia-Bearing Mice by New Platinum (II) Complexes

Antitumour activity of platinum analogues against human yolk sac tumours heterotransplanted in nude mice

Evaluation of Degradation Properties of Polyglycolide and Its Potential as Delivery Vehicle for Anticancer Agents

Contact Info

Product

Resources

About